Adage Capital Partners Gp, L.L.C. Aurinia Pharmaceuticals Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$10.0 - $14.52 $3.5 Million - $5.08 Million	-350,110 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $3.36 Million - $5.11 Million	-273,000 Reduced 43.81%	350,110 $4.55 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $2.94 Million - $3.72 Million	223,110 Added 55.78%	623,110 $9.18 Million
Q1 2020 May 15, 2020	BUY	$11.34 - $21.46 $4.54 Million - $8.58 Million	400,000 New	400,000 $5.8 Million

208

58.1M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.14B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.